ALTASCIENCES
Altasciences is proud to have conducted preclinical studies for Verve Therapeutics that support the development and advancement of Verve’s gene editing approach to treating cardiovascular diseases. Altasciences’ Seattle team performed intravenous preclinical studies, including supporting analyses of pharmacodynamic markers and whole liver DNA editing, in non-human primates, that show that a single intravenous infusion of Verve’s gene editor achieved a 59% reduction in blood low-density lipoprotein cholesterol (LDL-C) at two weeks, which has been maintained beyond six months post treatment. No adverse events were reported during the study and in studies of primary human hepatocytes, clear evidence of on-target editing was observed.
“We are excited to have supported the advancement of Verve’s gene editors for cardiovascular disease, and to have contributed to the development of an entirely new approach to treating heart disease, which remains the leading cause of death among men and women worldwide, ” says Mike Broadhurst, General Manager of Altasciences’ preclinical facility.
More information on Verve Therapeutics’ program can be found here .
About Altasciences
Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services . For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing , clinical pharmacology and proof of concept , bioanalysis , program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210312005344/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Estée Lauder Announces Actress Daisy Edgar-Jones as Newest Global Brand Ambassador8.1.2026 14:00:00 CET | Press release
Estée Lauder today announced that it has signed acclaimed British actress, Daisy Edgar-Jones, as its newest Global Brand Ambassador. Daisy will represent Estée Lauder skin care, makeup, and fragrance, with her first campaign debuting on February 2nd across print, digital and in-store. She joins Estée Lauder’s current roster of global talent including Ana de Armas, Bianca Brandolini, Carolyn Murphy, Imaan Hammam, IU, Karlie Kloss, Paulina Porizkova and Yang Mi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108459289/en/ Daisy Edgar-Jones for Estée Lauder “As an actress, I love how makeup can tell a story of who we are. I have always admired how Estée Lauder celebrates confidence and individuality in women. The legacy, elegance, and strength of the brand is so inspiring,” said Daisy Edgar-Jones. “It feels surreal to be part of the Estée Lauder family – and it truly feels like a family.” “Daisy is very much the breakout sta
Kinaxis Appoints Razat Gaurav as New CEO8.1.2026 14:00:00 CET | Press release
With over two decades of supply chain experience and a proven record of driving global growth Razat Gaurav is uniquely positioned to lead Kinaxis in its next phase of AI-driven innovation. Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced the appointment of Razat Gaurav as Chief Executive Officer (CEO) effective January 12, 2026, his official start date, at which time he will also join the Kinaxis Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108330975/en/ Razat Gaurav, Kinaxis CEO “After a rigorous search, the Board selected Razat to lead the company as CEO,” said Bob Courteau, Interim CEO and Board Chair at Kinaxis. “Razat’s twenty-five years of experience in supply chain solutions, his proven track record in advancing innovation-driven growth, and his passion for developing high-performing cultures make him uniquely qualified for this role. The Board looks forw
Liberty Latin America Expands Exclusive International Voice Managed Services Partnership with BTS to 22 Additional Caribbean Markets8.1.2026 13:30:00 CET | Press release
BTS, the leading provider, technology enabler, and trusted partner to CommTech players worldwide, has been appointed by Liberty Latin America (LLA) as the exclusive provider of International Voice Managed Services for 22 additional Caribbean markets. This expansion builds on the successful 2023 partnership, in which BTS was selected as the exclusive international voice provider for Costa Rica, Panama, Puerto Rico, and the U.S. Virgin Islands. With this agreement, BTS will now support International Long Distance (ILD) services across a total of 26 LLA markets. Effective January 1, 2026, BTS began handling ILD voice services for the newly added Caribbean markets, enabling greater service consistency, enhanced quality, and improved operational efficiency across LLA’s regional footprint. The 22 new markets incorporated under the expanded partnership include: Anguilla, Antigua, Bahamas, Barbados, Bonaire, British Virgin Islands, Cayman, Curaçao, Dominica, Grenada, Jamaica, Montserrat, Saba,
Det-Tronics Acquires Optronics8.1.2026 13:28:00 CET | Press release
Optronics is a global leader in optical gas detection products and solutions for high-hazard, mission-critical applications Det-Tronics, a global leader in fire and gas safety systems, has acquired Optronics, a Norway-based company that specializes in optical gas detection technologies. Det-Tronics is part of Spectrum Safety Solutions that is based in Stamford, CT. Optronics, founded in 2018, is a technology leader in high-end optical gas detection products and solutions for energy, marine and industrial applications. Optronics has a strong record of innovation, bringing leading products and expert solutions to market for its customers. (www.optronics-technology.com) “Det-Tronics’ strategy is built on growth, innovation and quality. Optronics and Det-Tronics are a perfect fit to grow our businesses, drive new innovations and lead the market with high quality and reliable products and solutions,” noted Johannes Mario Kahlert, President of Det-Tronics. “We are very excited for the path a
Virometix AG Announces Positive Data from Phase 1 Trial of V-212, a Fully Synthetic, Serotype-Independent Vaccine Development Candidate for the Prevention of Pneumococcal Disease8.1.2026 13:00:00 CET | Press release
V-212 was well tolerated and demonstrated an excellent safety profileRobust IgG responses were observed to all three antigens in the vaccineResults support further development of V-212 independently and in combination with approved pneumococcal conjugate vaccines (PCVs) Virometix AG, a clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced positive topline data from the Company’s Phase 1 trial of its lead asset V-212, a serotype-independent pneumococcal vaccine candidate, in development for the prevention of pneumococcal disease caused by Streptococcus pneumoniae (Spn) infections. The study evaluated safety and immunogenicity in healthy volunteers, with data demonstrating an excellent safety profile and robust immune responses across all three target antigens in the vaccine. Results support further development of V-212 independently and in combination with an approved PCV. “With the significant need for an effective serotype-independent vaccine, we ar
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom